Download Drug consumption statistics

The utilisation of drugs
(medicines)
is reflected
and described in the
Pharmaceutical
Consumption
Statistics.
JAMASOFT2017
1
There is a link (causal feedback)
(statistically significant and positive relationship)
Between
the level of pharmaceutical
consumption
and health statistics (life expectancy).
JAMASOFT2017
2
Using Drug
Consumption Data
Estimate of Disease
Prevalence
JAMASOFT2017
3
Pharmaceutical consumption by DDDs.
Pharmaceutical consumption
according to the
Anatomical Therapeutic Chemical
Classification
ATC/Defined Daily Dose (DDD)
system
JAMASOFT2017
4
Definition
Defined daily dose (DDD) is
defined as the assumed
average maintenance dose
per day for a drug used on
its main indication in
adults.
JAMASOFT2017
5
DDDs are assigned to each active ingredient(s) in a
given therapeutic class
by International Expert Consensus.
For instance,
the DDD for oral aspirin equals 3 grams, which is
the assumed maintenance daily dose to treat
pain in adults.
DDDs do not necessarily reflect the average
daily dose actually used in a given country.
DDDs can be aggregated within and across
therapeutic classes of the Anatomical
Therapeutic Chemical Classification (ATC).
JAMASOFT2017
6
The consumption of pharmaceuticals
is increasing across OECD countries not only in terms
of expenditure but also in terms of volume (or
quantity) of drugs consumed.
One of the factors contributing to the rise in
pharmaceutical consumption is the ageing of the
population, which leads to growing demand for drugs
to treat or at least control different ageing-related
diseases.
JAMASOFT2017
7
The trend rise
in pharmaceutical consumption is also observed in
countries where
the population ageing process is less advanced,
indicating that other factors
such as physicians’ prescription habits
or the degree of cost-sharing with patients
also play a role.
JAMASOFT2017
8
Pharmaceutical consumption
has a positive and statistically significant effect
on remaining life expectancy at age 40 and 60
years,
although the effect on life expectancy at birth
is small and not significant.
JAMASOFT2017
9
JAMASOFT2017
10
JAMASOFT2017
11
JAMASOFT2017
12
JAMASOFT2017
13
IMS Health
is the world’s leading
provider of market
intelligence to the
pharmaceutical and
healthcare industries.
JAMASOFT2017
14
The original name
of the company was
Intercontinental
Medical
Statistics
JAMASOFT2017
15
IMS
was founded in 1954.
JAMASOFT2017
16
IMS
is a healthcare informatics
organization
with
a global presence
in over 100 countries.
JAMASOFT2017
17
IMS Health
serves leading decision makers in health care,
including pharmaceutical manufacturers and
distributors,
providers, payers, government agencies,
policymakers, researchers
and the financial community.
JAMASOFT2017
18
IMS applies
leading-edge technologies to transform billions of pharmaceutical
transactions collected from thousands of sources into strategic
insights.
Interpreted and analyzed by IMS experts, these
insights are an unmatched source of
trends and perspectives
about the pharmaceutical marketplace – precise
market intelligence that can be translated into
action.
JAMASOFT2017
19
Virtually every major
pharmaceutical company
is a client of IMS
along with professional services firms,
the financial community, government
and regulatory agencies, and
agencies, researchers and educators.
JAMASOFT2017
20
IMS
tracks over 1 million
pharmaceutical products,
capturing 70% of all prescriptions
worldwide
and also provides market research
and consulting services to the
healthcare industry.
JAMASOFT2017
21
In addition
to its presence as a global leader of knowledge
regarding pharmaceutical products,
IMS also has extensive patient and physicianlevel data
to examine health care utilization and
expenditures.
JAMASOFT2017
22
The company draws
on its global technology infrastructure and
unique combination of in-depth,
sophisticated analytics,
on-shore and off-shore commercial
services,
and consulting platforms to help clients
better understand the performance and
value of medicines.
JAMASOFT2017
23
Data Sources
IMS processes billions of healthcare
transactions each year,
covering every major world market.
The company receives data from more than
139,000 data suppliers covering 730,000
individual dispensing sites, worldwide.
JAMASOFT2017
24
Data sources include
drug manufacturers,
wholesalers,
retail pharmacies,
hospitals,
long-term care facilities
and healthcare professionals.
JAMASOFT2017
25
The world’s largest pharmaceutical databases
provide a view into:
• Physician prescribing patterns and brand preferences,
• Healthcare classes of trade, including hospitals, pharmacies,
physicians’ offices, nursing homes and alternate care sites,
• Benchmarks and measurements within therapeutic categories,
• Prescription drugs and third-party reimbursement profiles,
• Profiles and trends of diagnoses, best practices, and treatment
patterns,
• Promotional campaign mix and effectiveness in the
professional and consumer areas,
• Modeling, measuring and benchmarking techniques for the
ambulatory treatment area,
• Global healthcare issues.
JAMASOFT2017
26
High priority areas include:
- Drug Utilization Trends and Expenditures,
– Analysis of national trends in prescription
drug utilization and office-based care,
– Examination of adoption of new therapies
among patient and physician
subpopulations,
– Evaluation of prescription use and
expenditures and factors that influence these
trends.
JAMASOFT2017
27
Moreover:
• Geographic Variations in Care Examination of
geographic variations in treatments, costs and
outcomes
• Ecologic studies examining how geographic
variation in prescription use (e.g., antibiotics)
is associated with specific outcomes (e.g.,
antimicrobial resistance) is reflected.
JAMASOFT2017
28
Moreover:
• Real-world practice
– Analysis of association between patient, physician, and
health system characteristics and practice patterns
– Establishment of best practices and quality metrics for
specific conditions or populations, including for preventive
care and screening
– Utilization trends and costs in specific medical areas, such
as oncology, cardiovascular disease or rare diseases where
orphan drugs or specialty drugs are used,
• Investigations of socioeconomic, racial, or ethnic
disparities in processes or outcomes of care.
JAMASOFT2017
29
IMS DATA ASSETS
Some of IMS Health’s core assets are described
below.
Other data are also available to address a broad
range of research questions (e.g., information
on drug development; data examining
specialty and biologic therapies; electronic
medical record data). Access further
information about key IMS data assets by
visiting the website.
JAMASOFT2017
30
IMS DATA ASSET
National Prescription Audit™
Provides weekly and monthly analyses of
prescription activity for all products,
reflecting what the pharmacist
dispenses to the consumer,
stratification by some patient and physician
characteristics possible.
JAMASOFT2017
31
Xponent™
Provides comprehensive prescriber data based on
actual prescription activity within the retail,
mail service, long-term care, and specialty
retail markets,
projects prescriptions generated across all
prescription channels, payment types (cash)
and product level for more than 800,000
prescribers monthly .
JAMASOFT2017
32
National
Disease and Therapeutic Index™
Provides data from nationally
representative audit of office-based
physicians; focus on patterns of
treatment and disease.
JAMASOFT2017
33
Supporting the
Lifecycle of Medicinal Products
IMS stands ready to help
throughout the development life cycle — from
the assessment of market potential in prelaunch stages through the intricacies of
product launch and, finally, through that
transition period when clients must consider
new options for products long on the
market.
JAMASOFT2017
34
JAMASOFT2017
35
There are a lot of variations
across countries in the
consumption of drugs
for the treatment.
JAMASOFT2017
36
The consumption of antibiotics varies
from a low of 9 DDDs per 1 000 people per day
in Switzerland
to a high of 32 in Greece.
JAMASOFT2017
37
As over-consumption of antibiotics
has been acknowledged to create bacterial resistance, many
countries have launched in recent years information
campaigns targeting physicians and/or patients in order to
reduce antibiotic consumption.
As a result, consumption has stabilised in many countries and
even decreased in some others (such as France, -Portugal and
the Slovak Republic).
By contrast, -consumption has risen between 2000 and 2007 in countries that had below-average initial levels of consumption (such as Denmark and Ireland).
JAMASOFT2017
38
Thanks for your attention.
JAMASOFT2017
39